These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181 [TBL] [Abstract][Full Text] [Related]
3. [Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology]. Jarema M Psychiatr Pol; 1995; 29(1):57-66. PubMed ID: 7878155 [TBL] [Abstract][Full Text] [Related]
4. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor. Nikolov IG; Chernozemsky IN; Idle JR IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343 [TBL] [Abstract][Full Text] [Related]
5. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Kallio J; Lindberg R; Huupponen R; Iisalo E Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Syvälahti EK; Lindberg R; Kallio J; De Vocht M Br J Clin Pharmacol; 1986 Jul; 22(1):89-92. PubMed ID: 2874826 [TBL] [Abstract][Full Text] [Related]
7. The effect of urine pH on debrisoquine phenotyping: application of an HPLC-method. Kallio J Int J Clin Pharmacol Ther Toxicol; 1990 May; 28(5):223-6. PubMed ID: 2163994 [TBL] [Abstract][Full Text] [Related]
8. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk. Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748 [TBL] [Abstract][Full Text] [Related]
10. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134 [TBL] [Abstract][Full Text] [Related]
11. Oxidation phenotyping with debrisoquine in Germany (East). Zschiesche M; Hanke W; Siegmund W; Franke G; Wilke A Pharmazie; 1990 Dec; 45(12):920-1. PubMed ID: 2100800 [TBL] [Abstract][Full Text] [Related]
12. Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations. Tacke U; Leinonen E; Lillsunde P; Seppälä T; Arvela P; Pelkonen O; Ylitalo P J Clin Psychopharmacol; 1992 Aug; 12(4):262-7. PubMed ID: 1527229 [TBL] [Abstract][Full Text] [Related]
14. Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population. Xu XM; Jiang WD Zhongguo Yao Li Xue Bao; 1990 Sep; 11(5):385-8. PubMed ID: 2130590 [TBL] [Abstract][Full Text] [Related]
15. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population. Vincent-Viry M; Muller J; Fournier B; Galteau MM; Siest G Clin Chem; 1991 Mar; 37(3):327-32. PubMed ID: 2004438 [TBL] [Abstract][Full Text] [Related]
16. [Study on the frequency distribution of debrisoquine hydroxylation deficiency in Chinese healthy Zang and Wei volunteers]. Kuang TY; Liao XM; Wang KY; Zhang Y; Lou YQ Yao Xue Xue Bao; 1991; 26(4):250-4. PubMed ID: 1957669 [TBL] [Abstract][Full Text] [Related]
17. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439 [TBL] [Abstract][Full Text] [Related]
18. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test]. Baumann P Encephale; 1986; 12(4):143-8. PubMed ID: 3792273 [TBL] [Abstract][Full Text] [Related]
19. Debrisoquine oxidation polymorphism in patients with chronic inflammatory bowel disease. Ladero JM; Benítez J; Serrano M; García-Paredes J; Diaz-Rubio M Ann Med; 1995 Oct; 27(5):555-8. PubMed ID: 8541031 [TBL] [Abstract][Full Text] [Related]